Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

A review of solifenacin in the treatment of urinary incontinence

Authors Ramandeep Basra, Con Kelleher

Published 8 February 2008 Volume 2008:4(1) Pages 117—128

DOI https://doi.org/10.2147/TCRM.S1274

Ramandeep Basra, Con Kelleher

Department of Gynaecology, Guys and St Thomas NHS Foundation Trust, London, England, UK

Abstract: Overactive bladder (OAB) is a prevalent condition which has an adverse effect on quality of life. The presence of urgency incontinence confers significant morbidity above and beyond that of OAB sufferers who are continent. The primary treatment for OAB and urgency incontinence is a combination of behavioral measures and antimuscarinic drug therapy. The ideal antimuscarinic agent should effectively relieve the symptoms of OAB, with the minimum of side effects; it should be available as a once-daily sustained release formulation and in dosage strength that allows easy dose titration for the majority of sufferers. Solifenacin succinate was launched in 2005, and has been shown in both short and long term clinical trials to fulfill these requirements. Solifenacin is a competitive M3 receptor antagonist with a long half-life (45–68 hours). It is available in two dosage strengths namely a 5 or 10 mg once-daily tablet. The efficacy and tolerability of solifenacin for the treatment of all symptoms of OAB has been evaluated in a number of large, placebo controlled, randomized trials. Long-term safety, efficacy, tolerability and persistence with treatment have been established in an open label 40 week continuation study.

Keywords: solifenacin, urinary incontinence, overactive bladder

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Activation of mTOR: a culprit of Alzheimer’s disease?

Cai Z, Chen G, He W, Xiao M, Yan LJ

Neuropsychiatric Disease and Treatment 2015, 11:1015-1030

Published Date: 9 April 2015

Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

Huang FYJ, Lee TW, Chang CH, Chen LC, Hsu WH, Chang CW, Lo JM

International Journal of Nanomedicine 2015, 10:463-473

Published Date: 9 January 2015

The mediating role of cytokine IL-6 on the relationship of FEV1 upon 6-minute walk distance in chronic obstructive pulmonary disease

Baldi S, Jose PE, Bruschi C, Pinna GD, Maestri R, Rezzani A, Bellinzona E, Fracchia C, Dacosto E, Crotti P, Montemartini S

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1091-1099

Published Date: 7 October 2014

Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment

Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, Murray TG

Clinical Ophthalmology 2013, 7:193-198

Published Date: 22 January 2013

Sustained-release G-CSF microspheres using a novel solid-in-oil-in-oil-in-water emulsion method

Liu G, Hong X, Jiang M, Yuan W

International Journal of Nanomedicine 2012, 7:4559-4569

Published Date: 17 August 2012

Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?

Tsolaki F, Gogaki E, Sakkias F, Skatharoudi C, Lopatatzidi C, Tsoulopoulos V, Lampoura S, Topouzis F, Tsolaki M, Kountouras J

Clinical Ophthalmology 2012, 6:45-47

Published Date: 6 January 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011